Teva Asks High Court To Ax Fed. Circ. Claim Construction Rule
Teva Pharmaceuticals USA Inc. urged the U.S. Supreme Court on Friday to reverse a Federal Circuit decision invalidating one of its patent for its multiple sclerosis drug Copaxone, claiming the appeals...To view the full article, register now.
Already a subscriber? Click here to view full article